

Clinical Trials Register

- Lamivudine - NUCA2003
- **Study Title**
- A Randomized, Multi-center, Single-Blind (Patient), Placebo Controlled, Phase II, Dose Ranging Study to Determine the Pharmacokinetics, Safety, and Preliminary Activity of Twice Daily GR109714X in Patients with Chronic Hepatitis B infection

Study Status	Completed
Number of Patients	27
Study Trial Design	Randomised, Dose Ranging, Single Blind, Parallel-design
Study Endpoints	Serum HBV DNA levels, HBeAg seroconversion, ALT/AST response
Treatments	Compound: Lamivudine, Dose: 2.5, 10, 50, 150, 300 mg Frequency: Twice a day
Participating Countries	Canada, USA
Publication Status	Publication not yet available